ArticleEuropean heart journal. Quality of care & clinical outcomes2024
Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence.
Article in European heart journal. Quality of care & clinical outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Pooled it
- Guidelines for the appropriate use of renal denervation systems in Japan: endorsed by the Japanese Society of Hypertension (JSH), the Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), and the Japanese Circulation Society (JCS), and their positioning in the JSH 2025 guidelines.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Guideline
- Cost-effectiveness of renal denervation: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Pooled it
- Cost-Effectiveness and Budget Impact Analysis of Radiofrequency Renal Denervation for Uncontrolled and Resistant Hypertension in Italy.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Renal denervation revisited: is patient selection the missing link between failure and success?Clinical hypertension · 2026Review
- Renal denervation for hypertension: cross-country cost-effectiveness insights from mainland China, Japan, and Thailand.Health economics review · 2025Article
- Renal Denervation for Hypertension: Current Evidence and Clinical Perspectives.Current atherosclerosis reports · 2025Review
- Beyond Blood Pressure: Emerging Pathways and Precision Approaches in Hypertension-Induced Kidney Damage.International journal of molecular sciences · 2025Review
- Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands.PharmacoEconomics - open · 2025Article
- Cost-Effectiveness of Radiofrequency Renal Denervation in Taiwan Based on Clinical Evidence and Regional Event Rates.Journal of clinical hypertension (Greenwich, Conn.) · 2025Article
- Cost-Effectiveness of Radiofrequency Renal Denervation for Uncontrolled Hypertension in Japan.Journal of clinical hypertension (Greenwich, Conn.) · 2024Article
- Catheter-Based Radiofrequency Renal Denervation in the United States: A Cost-Effectiveness Analysis Based on Contemporary Evidence.Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Balancing Affordability and Need: Should We Use Renal Denervation in Hypertension Management?Journal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain.REC, interventional cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
Abstract
aimsCatheter-based radiofrequency renal denervation (RF RDN) has recently been approved for clinical use in the European Society of Hypertension guidelines and by the US Food and Drug Administration. This study evaluated the lifetime cost-effectiveness of RF RDN using contemporary evidence. METHODS AND
resultsA decision-analytic model based on multivariate risk equations projected clinical events, quality-adjusted life years (QALYs), and costs. The model consisted of seven health states: hypertension alone, myocardial infarction (MI), other symptomatic coronary artery disease, stroke, heart failure (HF), end-stage renal disease, and death. Risk reduction associated with changes in office systolic blood pressure (oSBP) was estimated based on a published meta-regression of hypertension trials. The base case effect size of -4.9 mmHg oSBP (observed vs. sham control) was taken from the SPYRAL HTN-ON MED trial of 337 patients. Costs were based on National Health Service England data. The incremental cost-effectiveness ratio (ICER) was evaluated against the UK National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold of £20 000-30 000 per QALY gained. Extensive scenario and sensitivity analyses were conducted, including the ON-MED subgroup on three medications and pooled effect sizes. RF RDN resulted in a relative risk reduction in clinical events over 10 years (0.80 for stroke, 0.88 for MI, 0.72 for HF), with an increase in health benefit over a patient's lifetime, adding 0.35 QALYs at a cost of £4763, giving an ICER of £13 482 per QALY gained. Findings were robust across tested scenarios.
conclusionCatheter-based radiofrequency RDN can be a cost-effective strategy for uncontrolled hypertension in the UK, with an ICER substantially below the NICE cost-effectiveness threshold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.